Mariela Cortés-López

Mariela Cortés-López

Auto-generated profile, based on publicly available information

Mariela Cortés-López

New York Genome Center, New York

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MCMariela Cortés-López
Mariela Cortés-López
LSLaura Schulz
Laura Schulz
MEMihaela Enculescu
Mihaela Enculescu
Claudia ParetClaudia Paret
Claudia Paret
BSBea Spiekermann
Bea Spiekermann
JKJulian König
Julian König
Following CART-19 immunotherapy for B-cell acute lymphoblastic leukaemia (B-ALL), many patients relapse due to loss of the cognate CD19 epitope. Since epitope loss can be caused by aberrant CD19 exon 2 processing, we herein investigate the regulatory code that controls CD19 splicing. We combine high-throughput mutagenesis with mathematical modelling to quantitatively disentangle the effects of all mutations in the region comprising CD19 exons 1-3. Thereupon, we identify ~200 single point mutations that alter CD19 splicing and thus could predispose B-ALL patients to developing CART-19 resistance. Furthermore, we report almost 100 previously unknown splice isoforms that emerge from cryptic splice sites and likely encode non-functional CD19 proteins. We further identify cis-regulatory elements and trans-acting RNA-binding proteins that control CD19 splicing (e.g., PTBP1 and SF3B4) and validate that loss of these factors leads to pervasive CD19 mis-splicing. Our dataset represents a comprehensive resource for identifying predictive biomarkers for CART-19 therapy.

8 October 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
MCMariela Cortés-López
Mariela Cortés-López
LSLaura Schulz
Laura Schulz
MEMihaela Enculescu
Mihaela Enculescu
CPClaudia Paret
Claudia Paret
BSBea Spiekermann
Bea Spiekermann
JKJulian König
Julian König
During CART-19 immunotherapy for B-cell acute lymphoblastic leukaemia (B-ALL), many patients relapse due to loss of the cognate CD19 epitope. Since epitope loss can be caused by aberrant CD19 exon 2 processing, we herein investigate the regulatory code that controls CD19 splicing. We combine high-throughput mutagenesis with mathematical modelling to quantitatively disentangle the effects of all mutations in the region comprising CD19 exons 1-3. Thereupon, we identify ~200 single point mutations that alter CD19 splicing and thus could predispose B-ALL patients to CART-19 resistance. Furthermore, we report almost 100 previously unknown splice isoforms that emerge from cryptic splice sites and likely encode non-functional CD19 proteins. We further identify cis -regulatory elements and trans -acting RNA-binding proteins that control CD19 splicing (e.g., PTBP1 and SF3B4) and validate that loss of these factors leads to enhanced CD19 mis-splicing. Our dataset represents a comprehensive resource for potential prognostic factors predicting success of CART-19 therapy. Highlights: Mutations in relapsed CART-19 patients lead to CD19 mis-splicing High-throughput mutagenesis uncovers ~200 single point mutations with a potential role in CART-19 therapy resistance Many mutations generate non-functional CD19 proteins by activating cryptic splice sites RNA-binding proteins such as PTBP1 are key to the expression of properly spliced, CART-19 immunotherapy-sensitive isoforms

23 May 2022 in Research Square
Verified
Preprint
Open access
PDF file
NZNicole Ziegler
Nicole Ziegler
MCMariela Cortés-López
Mariela Cortés-López
FAFrancesca Alt
Francesca Alt
MSMaximilian Sprang
Maximilian Sprang
NLNadine Lehmann
Nadine Lehmann
JFJörg Faber
Jörg Faber
Despite massive improvements in the treatment of B-ALL through CART-19 immunotherapy, a large number of patients suffer a relapse due to loss of the targeted epitope. Mutations in the CD19 locus and aberrant splicing events are known to account for the absence of surface antigen. However, the molecular determinants are not fully enlightened so far. We applied deep sequencing to analyze the CD19 locus in a cohort of B-ALL patients and identified a blast-specific 2-nucleotide deletion in intron 2 that exists in 35% of samples at initial diagnosis. Remarkably, no disease-specific mutation in the coding region was detected. We show that this deletion affects the binding site of RNA binding proteins (RBPs) including PTBP1. Moreover, we show that downregulation of PTBP1 in 697 cells reduces CD19 total protein by increasing intron 2 retention. Isoform analysis in patient samples revealed that blasts, at diagnosis, express increased amounts of CD19 intron 2 retention compared to normal B cells. By RNAseq and qRT-PCR, we could identify several RBPs being deregulated in leukemic blasts.Our data suggest that loss of RBP functionality by mutations altering their binding motifs or by deregulated expression might harbor the potential for the disease-associated accumulation of therapy-resistant CD19 isoforms.

3 November 2023 in Blood
Verified
Journal Article
Open access
HLHanzhi Luo
Hanzhi Luo
MCMariela Cortés-López
Mariela Cortés-López
CTCyrus L. Tam
Cyrus L. Tam
MXMichael Xiao
Michael Xiao
IWIsaac Wakiro
Isaac Wakiro
MKMichael G. Kharas
Michael G. Kharas
Disclosures. Landau:Ultima Genomics: Research Funding; 10X Genomics: Research Funding; Pangea: Membership on an entity's Board of Directors or advisory committe